Buchang receives CSRC approval for its planned A-share IPO


We are very happy to report that Buchang Pharmaceuticals, China’s leading private traditional Chinese medicine company and a HAO II portfolio company, received listing approval from the China Securities Regulatory Commission (“CSRC”) on 13 July for its planned A-share IPO.

A link to the announcement on the CSRC’s website (in Chinese) can be found here.

Posted in Homepage News, Portfolio News.